PFE.US Overview

Pfizer's Development Plan: Pfizer has announced its development plan for the PD-1/VEGF bispecific antibody 707/PF'4404 in collaboration with 3SBIO, which is expected to exceed market expectations according to CMBI's research report.

Market Positioning: CMBI believes that the PD-1/VEGF bispecific antibody will become a cornerstone in tumor immunotherapy, and Pfizer is likely to leverage its internal pipeline and clinical execution to gain a competitive edge.

Impact on 3SBIO: The global value release of 707/PF'4404 is anticipated to be a significant catalyst for 3SBIO's growth, although CMBI has slightly adjusted its target price for the company from $37.58 to $37.43 while maintaining a Buy rating.

Short Selling Data: Pfizer's stock is experiencing short selling activity with a total of $47.20 million and a ratio of 10.495%, indicating some market skepticism despite the positive outlook on its drug development.

Collaboration Agreement: FOSUN PHARMA signed a US$2.1 billion collaboration agreement with Pfizer for its preclinical small molecule GLP-1 drug, YP05002, positioning it favorably in the market.

Financial Impact: CLSA raised its earnings forecasts for FOSUN PHARMA, adjusting net profit predictions for 2025-2027 upwards by 1% to 2.4%, reflecting the positive financial implications of the collaboration.

Target Price Increase: Following the agreement, CLSA increased its target prices for FOSUN PHARMA's H-/A-shares from $29.6/RMB40.2 to $31.6/RMB42.4, maintaining an Outperform rating.

Market Activity: FOSUN PHARMA's stock saw a short selling of $10.30 million with a ratio of 12.189%, indicating notable market activity surrounding the company.

US Tariff Plans: The US plans to impose nearly 100% tariffs on imported semiconductor chips, which could negatively impact the pharmaceutical sector, as indicated by Morgan Stanley's research report.

Market Reactions: The Hang Seng Healthcare Index dropped by 3%, reflecting market concerns over the upcoming US pharma tariffs and the influence of semiconductor tariffs, although the likelihood of tariff payments for licensing transactions remains low.